Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Silence to Present at Jefferies London Conference

11 Nov 2021 07:00

RNS Number : 0197S
Silence Therapeutics PLC
11 November 2021
 

 

Silence Therapeutics to Present at Jefferies London Healthcare Conference

 

 

11 November 2021

 

LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will present at the Jefferies London Healthcare Conference being held November 16-18, 2021.

The on-demand presentation will be available beginning on Thursday, November 18 at 8:00am GMT / 3:00am ET and can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available on the Company's website following the conference.

 

 

Enquiries:

 

Silence Therapeutics plc

Gem Hopkins, Head of IR and Corporate Communications

ir@silence-therapeutics.com

 

 

Tel: +1 (646) 637-3208

Investec Bank plc (Nominated Adviser and Broker)

Daniel Adams/Gary Clarence

 

  Tel: +44 (0) 20 7597 5970

European PR

Consilium Strategic Communications

Mary-Jane Elliott/ Angela Gray / Chris Welsh

silencetherapeutics@consilium-comms.com

 

Tel: +44 (0) 20 3709 5700

 

About Silence Therapeutics

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron-loading anemia conditions. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. For more information, please visit https://www.silence-therapeutics.com/.

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBMBBTMTBBTRB
Date   Source Headline
10th Aug 20114:41 pmRNSSecond Price Monitoring Extn
10th Aug 20114:35 pmRNSPrice Monitoring Extension
8th Aug 20114:35 pmRNSPrice Monitoring Extension
5th Aug 20114:40 pmRNSSecond Price Monitoring Extn
5th Aug 20114:35 pmRNSPrice Monitoring Extension
3rd Aug 20114:40 pmRNSSecond Price Monitoring Extn
3rd Aug 20114:35 pmRNSPrice Monitoring Extension
3rd Aug 20117:00 amPRNNotice of Allowance for New U.S. Patent
1st Aug 20114:40 pmRNSSecond Price Monitoring Extn
1st Aug 20114:35 pmRNSPrice Monitoring Extension
1st Aug 20117:00 amPRNGroup Reorganisation and Board Changes
18th Jul 20114:40 pmRNSSecond Price Monitoring Extn
18th Jul 20114:35 pmRNSPrice Monitoring Extension
12th Jul 20114:40 pmRNSSecond Price Monitoring Extn
12th Jul 20114:35 pmRNSPrice Monitoring Extension
8th Jul 20114:40 pmRNSSecond Price Monitoring Extn
8th Jul 20114:35 pmRNSPrice Monitoring Extension
6th Jul 20114:41 pmRNSSecond Price Monitoring Extn
6th Jul 20114:35 pmRNSPrice Monitoring Extension
5th Jul 20114:40 pmRNSSecond Price Monitoring Extn
5th Jul 20114:35 pmRNSPrice Monitoring Extension
1st Jul 20114:40 pmRNSSecond Price Monitoring Extn
1st Jul 20114:35 pmRNSPrice Monitoring Extension
30th Jun 20114:40 pmRNSSecond Price Monitoring Extn
30th Jun 20114:35 pmRNSPrice Monitoring Extension
29th Jun 20114:40 pmRNSSecond Price Monitoring Extn
29th Jun 20114:35 pmRNSPrice Monitoring Extension
28th Jun 20114:40 pmRNSSecond Price Monitoring Extn
28th Jun 20114:35 pmRNSPrice Monitoring Extension
23rd Jun 20114:41 pmRNSSecond Price Monitoring Extn
23rd Jun 20114:35 pmRNSPrice Monitoring Extension
17th Jun 20114:40 pmRNSSecond Price Monitoring Extn
17th Jun 20114:35 pmRNSPrice Monitoring Extension
16th Jun 20114:40 pmRNSSecond Price Monitoring Extn
16th Jun 20114:35 pmRNSPrice Monitoring Extension
13th Jun 20113:33 pmPRNResults of Annual General Meeting
9th Jun 20114:40 pmRNSSecond Price Monitoring Extn
9th Jun 20114:35 pmRNSPrice Monitoring Extension
8th Jun 20114:40 pmRNSSecond Price Monitoring Extn
8th Jun 20114:35 pmRNSPrice Monitoring Extension
6th Jun 20112:00 pmPRNPresentation at ASCO
1st Jun 20117:00 amPRNSilence Therapeutics Post-Fundraising Update
25th May 20111:56 pmPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
20th May 20119:26 amPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
19th May 20111:52 pmPRNTR-1: Notification Of Major Interest In Shares
19th May 201110:05 amRNSForm 8.3 - Silence Therapeutics]
19th May 20117:00 amPRNNew Data from Phase I Study with Atu027
19th May 20117:00 amPRNNew Data from Phase I Study with Atu027
18th May 20113:45 pmPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
18th May 20117:00 amPRNPublication of 2010 Annual Report and Notice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.